msos
msos · page 3
- Clinical Research
Cannabis Rescheduling is Here: Trump Signs Executive Order to Move Cannabis to Schedule III
After two years of speculation, rumours, stock swings, broken promises, and political theatre, President Donald Trump officially signed an executive order (EO) to push cannabis rescheduling through on Thursday (December 18).
- Industry Trends
Could Trump Actually Reschedule Cannabis This Time?
Cannabis Rescheduling fervour has once again reached dramatic levels following media reports that President Donald Trump is considering pushing through the long-touted move via an executive order.
- Industry Trends
Why Cannabis Stocks Are So Volatile: How Policy, Capital and Hype Shaped a Perpetual Rollercoaster
From the euphoric highs of 2018’s ‘green rush’ to the sharp corrections and structural stasis that have followed, cannabis equities have been among the most volatile financial assets since they first appeared on global markets.
- Investment & Finance
Trump Sends Cannabis Stocks Surging, Cantourage Brings in Investor Relations Help, & Mamedica Secures £4.5m
Cannabis Stocks Surge on Trump Video Global cannabis stocks have enjoyed a considerable, but likely temporary, run this week, after US President Donald Trump shared a video apparently endorsing the use of CBD for senior healthcare.
- Uncategorized
Cannabis Stocks Rally on Trump’s Cannabis Comments
North American cannabis stocks have rallied following former President Donald Trump’s apparent indications that he is warming to the idea of federal reform.
- Adult-Use
Cannabis CEOs don’t need federal legalization to grow their businesses
The CEOs of nine of the biggest cannabis companies in the US and Canada don’t have high hopes for federal legalization in 2022, reports Insider.
- Adult-Use
The States Reform Act is a long shot, but we’ll take it
There is more bad news from Quebec-based HEXO, who has announced that it is shuttering three production facilities — two in Ontario, one in Nova Scotia — two of which were only acquired in the last year or so.
- Adult-Use
Analysts say these Canadian weed stocks could rebound post-legalization
US Senate Majority Leader Schumer’s bill is unlikely to be passed, but it’s a good starting point for negotiations, said Owen Bennett, senior vice president of global tobacco and cannabis stocks at Jefferies Equity Research, on BNN Bloomberg.
- Companies
Why aren’t America’s biggest MSOs California dreamin’?
While 98% of cannabis sales in Florida are through multi-state operators like Trulieve, many are playing just a minor role in California’s massive marketplace, writes New Cannabis Ventures.
- CBD Market
Valens takes the Green Road south
Kelowna-based The Valens Company’s US market strategy is giving us hope for Canadian cannabis after making a $40 million deal (USD) in the American CBD market.
- Adult-Use
Three rules for long-term cannabis gains
Now that the stigma of investing in the cannabis industry has worn off, experts are predicting a flood of capital coming into the sector, particularly among MSOs in the US, according to Barron’s.
- Adult-Use
Wall Street picks MSOs over Canada
Despite good news like New York legalization and the SAFE banking act advancing, the cannabis capital market haven’t rebounded all the way, reports MarketWatch.
